Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

TFF Pharmaceuticals to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 26, 2020


TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will release its financial results for fourth quarter and full-year 2019 and business update on Thursday, March 26, 2020. The Company's management will host a conference call to discuss the financial results and provide a business update on recent corporate and clinical developments at 8:30 a.m. Eastern Time.

Conference Call Details:

Thursday, March 26, 2020, 8:30 a.m. Eastern Time (ET)

Domestic Dial-In Number: Toll-Free: (800) 816-3024

International Dial-In Number (857) 770-0106

Conference ID: 7695599

Webcast URL: https://edge.media-server.com/mmc/p/k9qym597

The conference call will also be broadcast live and available for replay for one month on the Company's website, https://tffpharma.com, in the Events Calendar of the Investors section. Please access the Company's website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.

About TFF Pharmaceuticals' Thin Film Freezing technology platform

TFF Pharmaceuticals' Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a "Brittle Matrix Particle," which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments, the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 39 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company's website at https://tffpharma.com.

###


These press releases may also interest you

24 nov 2020
After a year-long search for diverse early-stage startups, Established (the company behind Startup of the Year Summit) and .US announced that Jeenie was named the .US Veteran Startup of the Year winning $10,000 non-dilutive cash prize from Summit...

24 nov 2020
CorticoMetrics announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for THINQtm, its AI-based software for use by radiologists and neurologists providing quantitative information to augment patient...

24 nov 2020
In a release issued under the same headline on Friday, November 13, by Avricore Health Inc. , the units issued figure was meant to be 6,260,000, not 6,360,000. The corrected release follows: AVRICORE HEALTH INC. (the "Company" or "Avricore")...

24 nov 2020
VitalHub Corp. (the "Company" or "VitalHub") announced today it has filed its Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis report for the three and nine months ended September 30, 2020 and 2019 with...

24 nov 2020
InMed Pharmaceuticals Inc. ("InMed" or the "Company") , a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today...

24 nov 2020
The Minister Responsible for Government Administration and Chair of the Conseil du trésor, Sonia LeBel, today tabled additional appropriations totalling $10.1 billion, comprising $5.1 billion in sums to be voted and $5.0 billion in continuing...



News published on 19 march 2020 at 09:05 and distributed by: